Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Drugmaker Eli Lilly and Co. spent $1.59 million in the second quarter lobbying the federal government on an array of trade issues and health care reform.
The Indianapolis-based drugmaker lobbied on German and Greek pricing reforms and Polish and Italian market access. It lobbied on counterfeit medicines, Russian data exclusivity and financial derivatives according to a report filed with the clerk of the House of Representatives.
Lilly also lobbied on Medicaid and Medicare issues and hospital discounts tied to health care reform, which was passed in March by Congress and aims to cover millions of uninsured people.
The drugmaker's second-quarter spending total dropped 56 percent from the same quarter of 2009 and also represented a decrease from the $2.3 million it spent in the 2010 first quarter.
Besides Congress, Lilly also lobbied the U.S. Trade Representative, the Patent and Trademark Office, the Food and Drug Administration, and the departments of Health and Human Services, Commerce, State and Agriculture.